These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31932276)

  • 1. Can affordability and innovation coexist for medicines?
    Colbert A; Rintoul A; Simão M; Hill S; Swaminathan S
    BMJ; 2020 Jan; 368():l7058. PubMed ID: 31932276
    [No Abstract]   [Full Text] [Related]  

  • 2. New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines.
    Suleman F; Low M; Moon S; Morgan SG
    BMJ; 2020 Jan; 368():l4408. PubMed ID: 31932324
    [No Abstract]   [Full Text] [Related]  

  • 3. Pricing of pharmaceuticals is becoming a major challenge for health systems.
    Morgan SG; Bathula HS; Moon S
    BMJ; 2020 Jan; 368():l4627. PubMed ID: 31932289
    [No Abstract]   [Full Text] [Related]  

  • 4. Defining the concept of fair pricing for medicines.
    Moon S; Mariat S; Kamae I; Pedersen HB
    BMJ; 2020 Jan; 368():l4726. PubMed ID: 31932334
    [No Abstract]   [Full Text] [Related]  

  • 5. [An alternative and innovative Research and Development model to ensure access to medicines - Neglected diseases, neglected populations, and biomedical innovation system].
    Pécoul B
    Med Sci (Paris); 2016 Dec; 32(12):1049-1050. PubMed ID: 28044961
    [No Abstract]   [Full Text] [Related]  

  • 6. Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?
    Sarpatwari A; Avorn J; Kesselheim AS
    BMJ; 2020 Oct; 371():m3841. PubMed ID: 33032982
    [No Abstract]   [Full Text] [Related]  

  • 7. [What is the fair price of innovative therapy?].
    Fischer A; Dewatripont M; Goldman M
    Med Sci (Paris); 2020 Apr; 36(4):389-393. PubMed ID: 32356716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pandora's Prescription: The Pharmaceutical Pricing
    Pederson T
    FASEB J; 2017 Nov; 31(11):4661-4662. PubMed ID: 29093000
    [No Abstract]   [Full Text] [Related]  

  • 9. [The long path (s) of placing medicines on the market].
    Duguet C
    Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():13-17. PubMed ID: 30943154
    [No Abstract]   [Full Text] [Related]  

  • 10. Innovation-Innovation Tradeoffs in Drug Pricing.
    Sachs RE; Frakt AB
    Ann Intern Med; 2016 Dec; 165(12):871-872. PubMed ID: 27723887
    [No Abstract]   [Full Text] [Related]  

  • 11. Clearing the air: towards agreement about access to high cost cancer medicines.
    Lipworth W; Kerridge I; Ghinea N; Zalcberg J
    Ann Oncol; 2019 Jan; 30(1):143-146. PubMed ID: 30339243
    [No Abstract]   [Full Text] [Related]  

  • 12. Price transparency is a step towards sustainable access in middle income countries.
    Cernuschi T; Gilchrist S; Hajizada A; Malhame M; Mariat S; Widmyer G
    BMJ; 2020 Jan; 368():l5375. PubMed ID: 31932333
    [No Abstract]   [Full Text] [Related]  

  • 13. Access to medicines is not the business of the pharma industry.
    Brown PJ
    J Int Assoc Physicians AIDS Care (Chic); 2002; 1(1):9-11; discussion 12-4. PubMed ID: 12942664
    [No Abstract]   [Full Text] [Related]  

  • 14. Commentary: Reconsidering Pharmaceutical Research and Development Investments.
    Gagnon MA
    Healthc Policy; 2023 Feb; 18(3):25-30. PubMed ID: 36917451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Health Impact Fund: incentives for improving access to medicines.
    Banerjee A; Hollis A; Pogge T
    Lancet; 2010 Jan; 375(9709):166-9. PubMed ID: 20109894
    [No Abstract]   [Full Text] [Related]  

  • 16. Costs of Drug Development and Research and Development Intensity in the US, 2000-2018.
    Sertkaya A; Beleche T; Jessup A; Sommers BD
    JAMA Netw Open; 2024 Jun; 7(6):e2415445. PubMed ID: 38941099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creating reliable pharmaceutical distribution networks and supply chains in African countries: Implications for access to medicines.
    Tetteh E
    Res Social Adm Pharm; 2009 Sep; 5(3):286-97. PubMed ID: 19733829
    [No Abstract]   [Full Text] [Related]  

  • 18. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 19. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 20. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.